KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBT Margin (2019 - 2025)

Aurinia Pharmaceuticals' EBT Margin history spans 7 years, with the latest figure at 46.28% for Q4 2025.

  • For Q4 2025, EBT Margin rose 4432.0% year-over-year to 46.28%; the TTM value through Dec 2025 reached 40.33%, up 3716.0%, while the annual FY2025 figure was 40.33%, 3716.0% up from the prior year.
  • EBT Margin reached 46.28% in Q4 2025 per AUPH's latest filing, up from 43.5% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 46.28% in Q4 2025 to a low of 5511.05% in Q1 2021.
  • Average EBT Margin over 5 years is 356.28%, with a median of 26.68% recorded in 2023.
  • Peak YoY movement for EBT Margin: skyrocketed 14498500bps in 2021, then crashed -971bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 139.28% in 2021, then soared by 36bps to 88.59% in 2022, then surged by 34bps to 58.58% in 2023, then skyrocketed by 103bps to 1.96% in 2024, then surged by 2262bps to 46.28% in 2025.
  • Per Business Quant, the three most recent readings for AUPH's EBT Margin are 46.28% (Q4 2025), 43.5% (Q3 2025), and 31.65% (Q2 2025).